
GLP-1 Drugs: Navigating the Demand and Coverage Challenges in 2025
In 2025, the GLP-1 receptor agonists, originally developed as medications for diabetes, will undergo a major transformation in use, as they are now more commonly prescribed to treat obesity. Insurance Coverage and Employer Considerations Only a few GLP-1 drugs are offered by US insurers because their annual cost exceeds $10,000, mostly for obesity. Through 2023,…